Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
26 lessons
11mFollistatin 344 is sold online as a muscle-building peptide. It is not a peptide: at 344 amino acids it is a protein. No published human trial has tested the injected product, the only follistatin-based drug to reach randomized trials grew muscle without improving function, and lab testing of black-market vials found most of them were not what the label said.
10mTwo antibodies that block the myostatin/activin pathway are being tested alongside GLP-1 drugs to protect lean mass. Bimagrumab's phase 2 BELIEVE trial is published in Nature Medicine. Apitegromab is FDA-approved, but only for spinal muscular atrophy. Neither is a peptide or a pill.
12mA goal-by-goal map of the peptides people ask about most, scored on human evidence and regulatory status. The only ones with strong evidence are approved drugs; most of the rest are animal data. No vendors, no dosing.
11mNo peptide is FDA-approved for building muscle in healthy adults. Here is what the human trials actually measured for growth hormone secretagogues, IGF-1 analogs, MOTS-c and the GLP-1 drugs, where each sits on the evidence ladder, and what regulators and anti-doping rules say.
6mTesamorelin is the only FDA-approved GHRH analog. It targets deep belly (visceral) fat in a specific population. Here's what the trials actually found, including the muscle question.
9mRetatrutide often makes the first few weeks feel easy. The harder part is keeping protein, hydration, and training quality high enough to protect muscle while appetite stays low.
8mMOTS-c is moving beyond the vague mitochondrial hype cycle. The newest data suggests it may participate in membrane repair, which changes the recovery conversation.
9mScale weight can lie when appetite drops, water shifts, and training changes. This checklist shows the signals that matter more than a single number on the scale.
9mGLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
8mGLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.
8mNew MOTS-C data points to something more specific than a generic metabolism story: better muscle mitochondrial efficiency. Here's what that means in practice.
8mNew 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.
8mBPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mRetatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mNew 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.
7mWomen have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.
8mA Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
11mIGF-1 LR3 is a lab-modified copy of the IGF-1 hormone, built in 1992 as a research reagent. A 2026 review places it in the tier with no peer-reviewed human studies at all. It is not FDA approved, is regulated as a biologic rather than a peptide, and is prohibited in sport.
9mCJC-1295 and Ipamorelin are two of the most popular GH secretagogues used together. This guide explains the differences between CJC with DAC and without DAC, how to dose them, and how to build the right protocol for your goals.
10mThe largest systematic review of BPC-157 to date analyzed 36 studies and confirmed consistent healing outcomes across tendons, ligaments, bone, and muscle tissue. Here's what the data shows.
8mBoth MOTS-C and GHK-Cu are popular among serious lifters over 50 — but they work through completely different mechanisms. Here's how to choose, and why the best answer is often both.
10mThe biggest risk with GLP-1 weight loss drugs isn't the fat loss — it's the muscle you lose with it. Strategic peptide stacking can tip the balance toward true body recomposition.
10mRetatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.
9mRetatrutide is often marketed as muscle-sparing. The published scans tell a narrower story: mostly fat loss, some lean loss, and no head-to-head body-composition data against tirzepatide yet.
10mBPC-157 is showing remarkable promise in clinical research for rapid tissue regeneration. Learn how this pentapeptide works, what the data shows, and whether it's right for your recovery protocol.
10mDiscover how TB-500 promotes tissue repair, reduces inflammation, and supports recovery from injuries.
Also available at /blog for legacy links.